STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

STAT

MARCH 26, 2024

The bill would ban Chinese biotech companies “of concern” — and any pharmaceutical companies that work with them — from getting federal contracts in a bid to ensure national security. Meanwhile, the Biosecure Act, designed to reduce U.S.

Drug Pricing 227

Drug Pricing Insurance Coverage and Processing Diabetes Pharmaceutical Companies 227

Express Pharma

JANUARY 31, 2024

While there are several options for taming inflation in healthcare, prioritising prescription drug price control and placing a strong emphasis on preventive care emerge as key solutions, according to GlobalData. Gharat concludes: “Implementing controls over drug prices is a complex endeavour that demands careful balancing.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

STAT

MARCH 22, 2023

In the face of rising drug prices, health plan sponsors have quietly used a clever, but questionable tactic over the past few years to deflect costs. And now, some pharmaceutical companies are pushing back.

Drug Pricing 233

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 233

STAT

JANUARY 26, 2023

In her latest bid to address prescription drug prices, U.S. Federal Trade Commission to “closely scrutinize” two pending pharmaceutical company mergers over concerns that “rampant consolidation” will drive up costs for consumers. Elizabeth Warren (D-Mass.) is urging the U.S.

Drug Pricing 243

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 243

RX Note

APRIL 16, 2023

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Pharmaceutical industry also spent a lot of money on marketing.

Drug Pricing 40

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 40

STAT

MARCH 28, 2023

drug crisis has accelerated, the pharmaceutical industry has jumped into action — particularly when it comes to naloxone, the drug used to reverse opioid overdoses , STAT reports. … As the U.S.

Drug Pricing 242

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 242

STAT

NOVEMBER 1, 2023

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up to $50 million to settle allegations of purposely underpaying Medicaid rebates.

Drug Pricing 304

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 304

STAT

JULY 6, 2023

But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices.

Drug Pricing 235

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 235

Drug Channels

FEBRUARY 7, 2024

And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.

Drug Pricing 93

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 93

STAT

FEBRUARY 15, 2024

For several years , some of the world’s largest pharmaceutical companies that participate in a U.S. drug discount program overcharged the federal government and numerous hospitals by hundreds of millions of dollars, according to claims made in a recently unsealed lawsuit. and their number has grown over the years.

Hospitals 309

Hospitals Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 309

STAT

OCTOBER 7, 2022

… The drug-pricing law will still penalize pharmaceutical companies if they hike prices on medicines for patients who have private insurance, STAT says. The penalties may factor into decisions for pricing medicines as the new law begins to take effect. Enjoy, and see you soon.

Drug Pricing 210

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 210

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports.

Vaccines 220

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 220

STAT

FEBRUARY 8, 2024

A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceutical companies that will be testifying before Sen.   Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Bernie Sanders’ HELP Committee today. Read the rest…

Pharmaceutical Companies 258

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Vaccines 258

STAT

MARCH 21, 2024

As more states create dedicated boards to cap the costs of medicines, some drugmakers and their allies are pushing back with a controversial tactic — lobbying for legislation to set exemptions for so-called orphan drugs, which are used to combat rare diseases that afflict relatively small groups of patients.

Pharmaceutical Companies 308

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 308

STAT

OCTOBER 17, 2023

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

Pharmaceutical Companies 337

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 337

STAT

JANUARY 6, 2023

The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. Read the rest…

Pharmaceutical Companies 246

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 246

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

STAT

AUGUST 8, 2023

Amid concerns that the pharmaceutical industry unfairly wins monopolies on medicines, a new analysis finds there has been a whopping 200% increase in patents filed by companies that made few substantive changes to their drugs during a 15-year period. health care system to pay higher prices for medicines for extended periods.

Pharmaceutical Companies 205

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 205

STAT

JANUARY 19, 2023

In a bid to blunt competition and address rising drug costs, Sanofi is offering a warranty that will cover the cost for any hospital if a specific medicine fails to work, marking only the second time a major pharmaceutical company has taken such a step.

Hospitals 256

Hospitals Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 256

Digital Pharmacist

MARCH 19, 2024

From sweeping federal legislation aimed at reigning in costs to the unexpected maneuvers of drug manufacturers, the effects of these changes reverberate throughout the healthcare system. The Dynamics of Increasing Drug Prices The escalation of drug prices is a multifaceted issue, with various factors contributing to its rise.

Drug Pricing 52

Drug Pricing Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

NY Times

OCTOBER 13, 2020

Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.

Vaccines 61

Vaccines Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 61

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

STAT

JULY 6, 2023

Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us.

Drug Pricing 174

Drug Pricing Vaccines Diabetes Pharmaceutical Companies 174

Pharmaceutical Technology

MAY 17, 2023

The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. While negotiating drug prices is common practice in other major markets, CMS had not previously held the legal authority to do so.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

STAT

MARCH 7, 2024

— Pharma industry giants including Bristol Myers Squibb, Johnson and Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

Drug Pricing 318

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 318

STAT

SEPTEMBER 6, 2023

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

Drug Pricing 292

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 292

STAT

JANUARY 11, 2024

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

Drug Pricing 317

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 317

Pharmaceutical Technology

FEBRUARY 8, 2023

According to Roche, the company is expected to offset its losses through the growth of its multiple sclerosis drug, Ocrevus, and the hemophilia drug Hemlibra. The biopharma industry continues to remain resilient while facing mounting pressure on drug pricing and a downturn in demand for COVID-19 therapies.

Vaccines 78

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 78

Drug Channels

APRIL 19, 2021

Join the compliance community for dynamic discussions on the top risk areas for specialty pharmaceutical companies, including speaker programs, patient support programs, charitable donations, specialty pharmacy relationships, patient advocacy group interactions, mergers and acquisitions, medical affairs activities, drug pricing, transparency and more! (..)

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 40

STAT

DECEMBER 6, 2023

March-in rights are a major power that the government has, until now, been extremely reluctant to use — the Obama administration, for example, rejected the idea, in part because pharmaceutical companies say the threat of such action would disincentivize them from researching and making new medicines.

Drug Pricing 363

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 363

STAT

MARCH 4, 2024

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year. Earlier this year, Medicare sent its initial price offers  to the companies.

Drug Pricing 247

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 247

Express Pharma

SEPTEMBER 6, 2023

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Pharmaceutical Technology

JUNE 29, 2022

Orphan drug designations provide financial incentives for companies and developers, including “tax credits for qualified clinical testing”, “a Waiver of the Prescription Drug User Fee” that is currently at almost $3 million for a new drug, and “potential seven years of market exclusivity”.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 98

PharmaShots

MAY 15, 2023

Allyson Moellenhoff: Our Drug Discount Management platform supports all the solutions we have built for the stakeholders in our ecosystem. One of those product suites is Kalderos for Manufacturers, a web-based suite of tools for pharmaceutical companies that sits on top of the Drug Discount Management platform.

Drug Pricing 40

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Hospitals 40

Pharmaceutical Technology

DECEMBER 15, 2022

Post-early access/ATU, a negotiated price and reimbursement level is determined according to the clinical value rating (Service Médical Rend, SMR) and Amélioration du Service Médical Rendu (ASMR) rating, evaluated by the Transparency Commission (TC) of HAS. Early access/ATU drugs enter the French market earlier in Europe.

Drug Pricing 59

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 59

Viseven

JANUARY 13, 2023

Evaluation of drug efficiency on a dedicated market is a complex process that requires HEOR experts to measure multiple indicators to understand the actual market value of the product. So what do exactly HEOR experts do for the pharmaceutical companies and what HEOR-collected data is used for? What is HEOR Data?

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Dosage Drug Pricing 40